期刊文献+

人恶性黑色素瘤多发转移裸鼠动物模型的建立 被引量:1

The Establishment of a Model of Multiple Human Malignant Melanoma Metastases in Nude Mice
下载PDF
导出
摘要 目的探讨建立人恶性黑色素瘤多发转移裸鼠动物模型的方法,为进一步研究恶性黑色素瘤的发病机制提供动物模型。方法将MV3人黑色素瘤细胞注射于裸鼠背部皮下,待裸鼠背部皮下出现肿瘤后,通过病理学检查及免疫组化技术对动物模型进行鉴定。结果裸鼠皮下接种人黑色素瘤细胞28d后背部皮下相继出现肿瘤,肿瘤组织免疫组化结果显示S-100及HMB45阳性,肿瘤组织HE染色及肺、脾、肝、脑、肾各组织免疫组化结果显示各组织均出现不同程度转移灶,表明成功建立人黑色素瘤多发转移裸鼠模型。结论该研究选择来源于人的恶性黑色素瘤细胞MV3接种于裸鼠背部皮下,28d后成功建立了人黑色素瘤多发转移裸鼠动物模型,该模型为进一步研究黑色素瘤的生物学特性及新药开发提供了实验依据。 Objective To explore the way to establish a model of multiple human malignant melanoma metasta- ses in nude mice so as to provide animal models for further study of the pathogenesis of malignant melanoma. Method Human melanoma cells MV3 were injected into dorsal subcutaneous tissues of nude mice. After tumors appeared in dorsal subcutaneous tissues, the animal models were detected with pathological examina- tion and immunohistochemical techniques. Results 28 days later, nude mice successively had tumors in dorsal subcutaneous tissues after the injection, tumor pathological section immunohistochemistry showed that S-100 and HMB45 were positive, tissue pathological section immunohistochemistry of HE staining, lung, spleen, liver, brain, and kidney showed that all these tissues had metastases to different degrees, which indicated the establishment of a model of multiple human malignant melanoma metastases in nude mice. Conclusion The study chooses human melanoma cells MV3 to inject into dorsal subcutaneous tissues of nude mice and after 28 days, a successful model of multiple human malignant melanoma metastases in nude mice is established. The animal model can provide an experimental evidence for further research of biological characteristics of melano- ma and the development of new drugs.
出处 《保健医学研究与实践》 2015年第4期24-26,共3页 Health Medicine Research and Practice
关键词 人恶性黑色素瘤 BALB/cA-nude裸鼠 多发转移 Human malignant melanoma BALB/cA-nude mice Multiple metastases
  • 相关文献

参考文献10

二级参考文献69

  • 1崔正军,岑瑛.恶性黑色素瘤基因治疗的研究现状[J].华西医学,2004,19(3):513-514. 被引量:4
  • 2程磊,周梁.肿瘤干细胞的研究进展[J].肿瘤,2006,26(7):688-690. 被引量:6
  • 3Kantoff PW, Higano CS, Shore ND, et al. Sipuleucel-T immtmo-therapy for castration-resistant prostate cancer[J]. N EnglJ Med, 2010. 363 (5): 411-422.
  • 4Zarei S, Schwenter F, Luy P, et al. Role of GM-CSF signaling in cell-based tumor immunization[J]. Blood, 2009, 113(26): 6658-6668.
  • 5HodiFS, Buder M, Oble DA, et al. Immunologic and clinical effects of antibody blockade of cytotoxic T lymphocyte-associated antigen 4 in previously vaccinated cancer patients[J]. Proc Nail Acad Sci U S A, 2008, 105(8): 3005-3010.
  • 6Gajewski TF, LouahedJ, Brichard VG. Gene signature in melanoma associated with clinical activity: a potential due to unlock cancer im- munotherapy[J]. Cancer J, 2010, 16(4):399-403.
  • 7Atkins MB, Lotze MT, Dutcher.JP, et al. High-dose recombinant interleukin 2 therapy for patients with metastatic melanoma: analysis of 270 patients treated between 1985 and 1993[J].J Clin Oncol, 1999, 17(7): 2105-2116.
  • 8Schwartzentruber DJ, Lawson DH, RichardsJM, et al. gpl00 peptide vaccine and interleukin-2 in patients with advanced melanoma[J]. N EnglJ Med, 2011, 364(22): 2119-2127.
  • 9Zhang L, Kerkar SP, Yu Z, et al. Improving adoptive T cell therapy by targeting and controlling IL-12 expression to the tumor environ- ment[J]. Mol Ther, 2011, 19(4): 751-759.
  • 10Petrella TM, Belnager K. Interleukin-21 (IL-21) activity in patients with metastatic melanoma (MM) [J]. j Cfin Oncol, 2010, 28: 15s(ab- stract 8507).

共引文献41

同被引文献7

引证文献1

二级引证文献1

相关作者

内容加载中请稍等...

相关机构

内容加载中请稍等...

相关主题

内容加载中请稍等...

浏览历史

内容加载中请稍等...
;
使用帮助 返回顶部